News

Stereotaxis STXS, a global leader in surgical robotics for minimally invasive endovascular intervention, recently announced the successful completion of the first U.S. commercial procedures using its MAGiC Sweep catheter.

The landmark cases were performed at the Deborah Heart and Lung Center in New Jersey. The case result emphasized the catheter’s ability to deliver precise, stable, and safe navigation during mapping of arrhythmias across atrial and ventricular chambers. The enhanced mapping resolution is likely to provide cardiologists with “a more accurate, detailed map of complex anatomy,” a critical advantage in diagnosing and treating cardiac arrhythmias. MAGiC Sweep maintained stable tissue contact, produced clear electrogram signals, and avoided ventricular ectopy, calling the innovation “a significant leap forward” for robotic electrophysiologists.

MAGiC Sweep is the first and only robotically navigated HD mapping catheter, allowing physicians to combine robotic precision with advanced mapping capabilities. By enabling accurate localization of arrhythmogenic tissue, it supports more targeted and effective ablation therapy.

The company’s shares have gained 18.9% in the year-to-date period against the industry’s 8% decline. The S&P 500 has increased 9.9% in the same time frame.

Image Source: Zacks Investment Research

Commercial Launch and Regulatory Pathway

Following FDA clearance in July, Stereotaxis has begun the commercial launch of MAGiC Sweep in the United States. The company has also submitted an application seeking regulatory approval for the catheter in Europe, reflecting its intent to scale adoption globally. With its pioneering role in robotic-assisted interventions, Stereotaxis positions MAGiC Sweep as a transformative tool that can expand physician confidence in robotics and broaden patient access to minimally invasive therapies.

Building on MAGiC Catheter Validation

This milestone builds upon the company’s earlier clinical progress with its MAGiC ablation catheter. Peer-reviewed first-in-human results, published in the Journal of Interventional Cardiac Electrophysiology, demonstrated a 94% acute efficacy rate across 67 patients, with short procedure times and a low adverse event profile. Physicians highlighted improved catheter stability, steady ablation performance, and reduced irrigation rates — advances especially valuable for patients with compromised cardiac or renal function. Together, the MAGiC ablation and mapping catheters strengthen Stereotaxis’ robotic ecosystem, offering an integrated suite for diagnosis and treatment of arrhythmias.

Industry Impact and Market Dynamics

Per a report by Future Market Insights, theglobal marketfor robotic catheterization systems is estimated to be worth $54.4 million in 2025 and is anticipated to reach $190.2 million by 2035.

The introduction of MAGiC Sweep represents a pivotal step in modernizing EP procedures. High-density mapping is essential for identifying arrhythmogenic tissue, and Stereotaxis’ ability to integrate this with robotic navigation sets it apart in an increasingly competitive market. Industry adoption may accelerate as physicians validate the benefits of precision, stability, and safety in real-world use.

While STXS’ shares have lagged broader indices year to date, the addition of MAGiC Sweep to its commercial portfolio is expected to enhance growth prospects and strengthen its credibility within the innovation-driven cardiac ablation segment.

Stereotaxis Inc. Price

STXS’ Zacks Rank & Stocks to Consider

Currently, STXS has a Zacks Rank #3 (Hold).

Some better-ranked stocks in the broader medical space that have announced quarterly results are Medpace Holdings, Inc. MEDP, West Pharmaceutical Services, Inc. WST and Boston Scientific Corporation BSX.

Medpace Holdings, sporting a Zacks Rank #1 (Strong Buy) at present, reported second-quarter 2025 EPS of $3.10, which beat the Zacks Consensus Estimate by 3.3%. Revenues of $603.3 million outpaced the consensus mark by 11.5%. You can see the complete list of today’s Zacks #1 Rank stocks here.

Medpace Holdings has a long-term estimated growth rate of 11.4%. MEDP’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 13.9%.

West Pharmaceutical reported second-quarter 2025 adjusted EPS of $1.84, which outpaced the Zacks Consensus Estimate by 21.9%. Revenues of $766.5 million surpassed the Zacks Consensus Estimate by 5.4%. It currently flaunts a Zacks Rank #1.

West Pharmaceutical has a long-term estimated growth rate of 8.5%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.

Boston Scientific reported second-quarter 2025 adjusted EPS of 75 cents, which beat the Zacks Consensus Estimate by 4.2%. Revenues of $5.06 billion surpassed the Zacks Consensus Estimate by 3.5%. It currently carries a Zacks Rank #2 (Buy).

Boston Scientific has an estimated long-term growth rate of 14%. BSX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.1%.

Higher. Faster. Sooner. Buy These Stocks Now

A small number of stocks are primed for a breakout, and you have a chance to get in before they take off.

At any given time, there are only 220 Zacks Rank #1 Strong Buys. On average, this list more than doubles the S&P 500. We’ve combed through the latest Strong Buys and selected 7 compelling companies likely to jump sooner and climb higher than any other stock you could buy this month.

You'll learn everything you need to know about these exciting trades in our brand-new Special Report, 7 Best Stocks for the Next 30 Days.

Download the report free now >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.